Document is current
Any future updates will be listed below
-
Authors
Hermansen, Johanne U. https://orcid.org/0000-0003-3830-2277
Athanasiadis, Paschalis
Yin, Yanping
Rise, Anne-Sofie F.
Arribas, Alberto J.
Cascione, Luciano https://orcid.org/0000-0002-4606-0637
Russnes, Hege G.
Helland, Åslaug
Mato, Anthony R.
Bertoni, Francesco https://orcid.org/0000-0001-5637-8983
Tjønnfjord, Geir E.
Aittokallio, Tero https://orcid.org/0000-0002-0886-9769
Skånland, Sigrid S. https://orcid.org/0000-0003-1630-356X
- License Information
-
More Information
Article History
Received: 2 September 2024
Revised: 16 June 2025
Accepted: 9 July 2025
First Online: 23 July 2025
Competing interests
: ÅH has received research support from AstraZeneca, BMS, EliLilly, GSK, Incyte, Novartis, Roche, Ultimovacs, the Norwegian Cancer Society, The regional health authorities in Norway. Have given talks and advise to pharma companies, and all honoraria are going to the hospital (Abbvie, AstraZeneca, BMS, EliLilly, Janssen, Medicover, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda). ARM has had a consulting or advisory role for AstraZeneca, TG Therapeutics, AbbVie/Genentech, Pharmacyclics, Adaptive Biotechnologies, Johnson & Johnson, Acerta Pharma/AstraZeneca, Loxo/Lilly, Curio/Vaniam Group, Merck, Bristol Myers Squibb/Pfizer, PerView, DAVA Oncology, BMS, Genmab, AXIS Education, and PER; and has received research funding from Regeneron, TG Therapeutics, Sunesis Pharmaceuticals, Loxo, AbbVie/Genentech, Pharmacyclics, Adaptive Biotechnologies, Johnson & Johnson, Acerta Pharma/AstraZeneca, DTRM, Genmab, and Nurix. FB has received institutional research funds from ADC Therapeutics, Bayer AG, BeiGene, Floratek Pharma, Helsinn, HTG Molecular Diagnostics, Ideogen AG, Idorsia Pharmaceuticals Ltd., Immagene, ImmunoGen, Menarini Ricerche, Nordic Nanovector ASA, Oncternal Therapeutics, Spexis AG; consultancy fee from BIMINI Biotech, Floratek Pharma, Helsinn, Immagene, Menarini, Vrise Therapeutics; advisory board fees to institution from Novartis; expert statements provided to HTG Molecular Diagnostics; travel grants from Amgen, Astra Zeneca, iOnctura. GET has received research grants from Mundipharma and Alexion Pharmaceuticals, advisory board honoraria from Alexion Pharmaceuticals and Janssen-Cilag, and lecture honoraria from Novartis, Janssen-Cilag, Alexion Pharmaceuticals, and Mundipharma. SSS has received consulting fees from AstraZeneca, BeiGene and Janssen; and research support from BeiGene and TG Therapeutics. The other authors declare no competing financial interests.
